Indapamida Zentiva (Indapamide)

Indapamide blocks the sodium‑chloride cotransporter in the distal convoluted tubule of the kidney. This inhibition reduces reabsorption of sodium and chloride, leading to increased urine output, lower plasma volume, and decreased peripheral vascular resistance, which together lower blood pressure and reduce edema.

The specific dose of Indapamida Zentiva is determined by the prescribing clinician based on the patient’s medical condition, response to therapy, and renal function. Dosage adjustments are individualized, and patients should follow the prescriber’s instructions without self‑adjusting the amount.

Safety data for indapamide in pregnancy and lactation are limited. It should only be used if the potential benefit justifies the possible risk to the fetus or infant. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss alternatives with their healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Indapamide belongs to the thiazide‑like class, offering potent antihypertensive effects with a lower incidence of metabolic disturbances compared with classic thiazides. Compared with loop diuretics, it is less powerful for rapid fluid removal but is preferred for long‑term blood pressure control and mild to moderate edema.

Indapamida Zentiva should be stored at temperatures below 25 °C, in its original packaging, and protected from moisture and direct sunlight. Keeping the tablets in a dry, cool environment helps maintain their stability and potency throughout the shelf life.

Indapamida Zentiva is taken orally, usually with a glass of water. It can be taken with or without food, but patients should follow the prescriber’s guidance on timing, especially if other medications are involved, to ensure optimal absorption and effect.

Serious risks include severe electrolyte imbalances (especially low potassium or sodium), dehydration, acute gout attacks, and rare blood disorders such as agranulocytosis. Patients should be monitored for signs of these conditions and seek immediate medical attention if symptoms like muscle weakness, severe abdominal pain, or rash develop.

Indapamida Zentiva is contraindicated in patients with known hypersensitivity to indapamide or other sulfonamide drugs, severe renal impairment, and in those with uncontrolled electrolyte disturbances. Caution is also advised for individuals with severe liver disease, gout, or those taking interacting medications such as lithium.